Conditions: Overactive Bladder
Keywords: Overactive Bladder Incontinence Solifenacin Women Postoperative
Allocation: RANDOMIZED | Intervention model: SINGLE_GROUP
Enrollment: 1
Healthy volunteers: yes

Brief summary:
The purpose of this study is to determine whether treatment with anti-muscarinic medications following sub-urethral sling procedures improves overall subjective and objective outcomes in women with mixed incontinence with primary stress symptoms.

Detailed description:
Women with mixed incontinence with primary stress symptoms undergoing Sub-Urethral Sling Procedures will be randomized to peri-operative placebo or solifenacin. Subjects in the placebo group will take orally once daily for 9 weeks. Subjects in the Solifenacin group will take orally once daily for 9 weeks.

Arms:
arm 1: Placebo Orally 9 weeks once daily. arm 2: Solifenacin Orally 9 weeks once daily.

Interventions: intervention 1: Solifenacin intervention 2: Placebo
Intervention descriptions: intervention 1: Solifenacin is used to treat overactive bladder. It works by relaxing the bladder muscles to prevent urgent, frequent, or uncontrolled urination. Take orally once daily for 9 weeks. intervention 2: Take orally once daily for 9 weeks.

Protocol document: